Patents by Inventor Philippe Paul Saudan

Philippe Paul Saudan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220331110
    Abstract: The invention concerns a bone graft material for use in a spinal fusion method, wherein the material comprises i) a composition for forming a matrix, comprising at least a first matrix material precursor component and a second matrix material precursor component, capable of forming a matrix by crosslinking of the precursor components under appropriate conditions; and ii) a bioactive factor, which is biologically active to stimulate bone formation between two vertebrae, and for effecting or supporting spinal fusion; wherein the spinal fusion method comprises the steps of applying a cage in between the two vertebrae, which is not pre-filled with the bone graft material; and subsequently applying the bone graft material adjacent to and/or into the cage, such that essentially the entire remaining volume between the two vertebrae is filled with the bone graft material. The invention allows for ease of use while forming a more homogeneous matrix.
    Type: Application
    Filed: September 21, 2020
    Publication date: October 20, 2022
    Inventors: Lorenz Vogt, Philippe Paul Saudan, Alistair Simpson Irvine
  • Publication number: 20220202987
    Abstract: Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.
    Type: Application
    Filed: February 14, 2022
    Publication date: June 30, 2022
    Inventors: Lorenz Vogt, Alistair Simpson Irvine, Philippe Paul Saudan
  • Patent number: 11266762
    Abstract: Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 8, 2022
    Assignee: KUROS BIOSURGERY AG
    Inventors: Lorenz Vogt, Alistair Simpson Irvine, Philippe Paul Saudan
  • Publication number: 20190275197
    Abstract: Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.
    Type: Application
    Filed: March 6, 2019
    Publication date: September 12, 2019
    Inventors: Lorenz Vogt, Alistair Simpson Irvine, Philippe Paul Saudan